Medicare patients get faster care—if insurers don't raise premiums to compensate
H.R. 8377 — Stop Deadly Denials Act of 2026 · Filed by Ro Khanna (D-CA) · 6 cosponsors · Introduced Apr 20, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits Medicare Advantage plans from requiring prior authorization (advance approval from insurers before patients receive care) for most medical services starting January 2027, and blocks the federal government from testing prior authorization models in traditional Medicare. It also requires physician review of any AI-driven coverage denials and mandates public notice-and-comment before testing new payment models.
Why we flagged it
The bill's core mechanism is removing a procedural barrier (prior authorization) that insurers use to delay or deny care, and restricting AI-driven denials without physician oversight. This is consumer protection regulation, not a tax or spending measure.
What the text implies
- Eliminates a key cost-control tool for Medicare Advantage plans; insurers may offset by raising premiums, narrowing provider networks, or increasing cost-sharing on other services not covered by the ban.
- The physician-review requirement for AI denials may create bottlenecks if not resourced adequately, potentially delaying coverage decisions rather than accelerating them.
The full analysis lists 5 implications of this text.
Who stands to gain
healthcare providers (reduced administrative burden from prior authorization requests); pharmaceutical companies (faster patient access to drugs, though Part D carve-out limits impact)